A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non-adjuvanted Trivalent Influenza Vaccine Fluzone in Children 6 to less than 72 Months of Age.

Trial Profile

A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non-adjuvanted Trivalent Influenza Vaccine Fluzone in Children 6 to less than 72 Months of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine (Agriflu) (Primary) ; MF 59
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Feb 2012 Planned end date changed from 1 Aug 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top